Protein-protein interaction (PPIs) ..................... 1, 61, 89,
127, 137, 157, 169, 170, 179, 187–189, 193,
217, 258, 279
Protein sample......................................................... 93, 95,
106–109, 112, 130, 131, 146, 204–206
Protein stability ............................................................. 146
Proteomics.....................17, 32, 38, 41–58, 93, 126, 285
Proteus program .................................................. 243, 247
PSD-95/Discs Large/ZO-1 (PDZ).........................1–14,
17–39, 41–58, 61–72, 75–86, 89–121, 125–132,
137–147, 149–176, 179–190, 193–215,
217–232, 237–253
domains ..................................... 3, 18, 41, 61, 75, 89,
126, 137, 143, 149, 152, 179, 194, 217, 230
inhibitors ................................................................. 159
lipids..................................................................... 75–86
proteins ...........................................19, 34, 76, 84, 85,
126, 137, 141, 143, 146, 150, 197, 219, 222,
224, 226, 231, 237, 250
Purification .....................................4, 8, 9, 17–39, 42–45,
47–49, 51, 52, 59, 62, 106, 109, 138–140, 146,
162, 170, 175, 181, 183, 198–206, 213
Purity ....................................................24, 37, 51, 52, 76,
90–92, 99, 103, 105–110, 139, 165, 166, 194,
204, 213
Q
Quality control ........................................ 25, 29, 118, 120
Quantification ............................................ 20, 46, 47, 58,
61, 91, 92, 95, 107, 108, 140, 207
R
Rational design..................................................... 277–286
Replication..................................221, 226, 227, 230, 232
S
SA sensor chip ............................................. 77, 79, 84, 85
Screening .................................................... 2–4, 7, 10, 11,
13, 14, 159, 163, 279–282, 284, 286
Scribble ............................................... 125–132, 138–140,
145, 223–226, 231, 261, 267–269
Scribble module .......................................... 125, 127, 128
Sensor chip (SA)................................................. 77, 81, 82
SH3-containing guanine nucleotide exchange
factor (SGEF) .................................. 128, 139, 145
Solid-phase peptide synthesis ............................. 159, 163,
165, 166, 193, 200, 206
Specificity ........................................... 69, 70, 75, 90, 126,
127, 137, 138, 196, 197, 219, 238, 244, 258,
278, 279
Stability ...................................... 86, 90, 97–99, 104, 105,
114–119, 146, 151, 152, 162, 171, 173, 188,
223, 237–239, 241, 262, 269, 283
Stroke...................................................158, 159, 163, 172
Structural biology ......................................................... 282
Structure ..................................................... 90, 91, 97, 99,
114, 116, 118, 126, 127, 130, 132, 149, 150,
217, 237, 241, 242, 244, 247, 248, 258, 277,
278, 280, 282–285
T
Tight junction (TJs)............................217, 222, 259–261
Two-hybrid array ............................................. 11–13, 126
V
Virus...........................140, 221–223, 225–227, 230, 232
X
X-ray crystallography .................127, 129, 130, 282, 284
Y
Yeast strains ............................................. 2, 4, 6, 9, 11, 14
Yeast two-hybrid (Y2H) ........................... 1–14, 126, 230
292
PDZ MEDIATED INTERACTIONS: METHODS AND PROTOCOLS
Index